Background. Vitamin D deficiency and insufficiency and the metabolic syndrome are two common health issues worldwide. The association between these two health problems is subject to debate. Objectives. This study aims to investigate the association between vitamin D deficiency or insufficiency and the metabolic syndrome in a sample of osteoporotic postmenopausal women attending a family practice clinic in Amman -Jordan. Material and Methods. This was an observational cross sectional study. It was carried out in the family practice clinic in Jordan University Hospital. The study included all postmenopausal osteoporotic women attending the clinic between June 2011 and May 2012, yielding a total of 326 subjects. The association between metabolic syndrome and serum vitamin D levels was investigated. Results. Waist circumference, body mass index, triglycerides and fasting blood sugar were significantly higher among postmenopausal women with metabolic syndrome, but HDL cholesterol was significantly lower (p < 0.05). The prevalence of metabolic syndrome among all study participants was 42.9%. Triglycerides and LDL cholesterol were significantly higher among women deficiency or insufficiency (p < 0.05). The prevalence of vitamin D deficiency or insufficiency was 45.7%. Among patients with metabolic syndrome, the prevalence of vitamin D deficiency or insufficiency was 50.7%. Conclusions. Findings of the current study suggest a lack of relationship between serum vitamin D and metabolic syndrome. However, a significant inverse relationship was found between serum vitamin D levels and both serum triglycerides and LDL levels (Adv Clin Exp Med 2015, 24, 2, 245-250).
ORIGINAL PAPERS
The metabolic syndrome is another important health issue among postmenopausal women [3] . Studies from different parts of the world have revealed that the prevalence of the metabolic syndrome reaches as high as 41.5% among postmenopausal women [4, 5] .
The association between vitamin D levels and the metabolic syndrome is the subject of considerable debate, and conflicting results have been found regarding this issue [2] . Some studies suggest that vitamin D deficiency could be a risk factor for the development of the metabolic syndrome [6] [7] [8] . On the other hand, there are studies that have shown a lack of any association between vitamin D levels and the metabolic syndrome [2, 9] . Further research is needed in this area.
Epidemiological studies have suggested that vitamin D deficiency could be related to individual components of the metabolic syndrome rather than being related to the syndrome itself. The findings of such studies suggest an inverse relationship between vitamin D levels and serum glucose or dyslipidemia [10] [11] [12] .
To the authors' knowledge, little research has been conducted in Jordan about the relationship between vitamin D levels and the metabolic syndrome, including its individual components. This study aims to investigate the association between vitamin D deficiency or insufficiency and the metabolic syndrome in a sample of osteoporotic postmenopausal female patients of a family practice clinic in Amman, Jordan.
Material and Methods
This was an observational cross-sectional study. It was carried out at the family practice clinic of Jordan University Hospital, the teaching hospital of Jordan University. The study included all the postmenopausal osteoporotic women fulfilling, the inclusion criteria described below, who were treated at the clinic period between June 2011 and May 2012, yielding a total of 326 subjects.
The research was approved and funded by the Deanship of Academic Research at Jordan University. All the subjects included provided verbal consent to participate in the study.
The inclusion criteria were as follows: 1) older than 40 years; 2) undergoing primary menopause [13] ; 3) diagnosed with primary osteoporosis, confirmed by a recent dual-energy X-ray absorptiometry (DXA) scan followed by the appropriate appraisals to rule out secondary osteoporosis [14] ; and 4) having a serum vitamin D measurement within the previous 3 months. The researchers required that all possible study subjects should have a recent vitamin D measurement regardless of the reason for which the test was performed.
Osteoporosis was defined on the basis of assessments of bone mineral density (BMD). According to the WHO criteria, osteoporosis is defined as "a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of < -2.5 SD)") [15] . The BMD was measurements were carried out using a Lunar iDXA (GE Healthcare). Measurements were done at two sites: the lumbar spine (L1-L4), and the total hip.
Serum 25-hydroxy vitamin D levels were measured using the ARCHITECT 25-OH assay, which is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of 25-hydroxyvitamin D in human serum and plasma. The reference values are: less than 25 nmol/L is deficient; between 25 and 74 nmol/L is insufficient; more than 74 nmol/L is: normal.
The metabolic syndrome was diagnosed using the National Cholesterol Education Program, Adult Treatment Panel III. Subjects were considered to have the metabolic syndrome if they had 3 or more of the following abnormalities: abdominal obesity: (waist circumference > 88 cm), high blood pressure: (systolic blood pressure ≥ 135 mm Hg and/or diastolic blood pressure ≥ 85 mm Hg, or if they were on antihypertensive medications), hypertriglyceridaemia: (serum trigliceryde level ≥ 150 mg/dL), low HDL-cholesterol (< 50 mg/dL), high fasting blood glucose (≥ 110 mg/dL, or if they were on anti-diabetic medications) [16] .
Data regarding DXA scan result, age, serum vitamin D, serum calcium, serum phosphorus, serum triglycerides, serum HDL, serum LDL and fasting blood sugar were extracted from the patient's' medical records by a trained research assistant. The research assistant measured the waist circumference, height and weight of each participant and calculated the body mass index [17] . Blood pressure was measured by a nurse at the clinic using a suitable cuff sphygmomanometer while the patient was in the sitting position. The mean of 3 readings separated by 1-min intervals was recorded.
The data were analyzed using SPSS 18 software (IBM Corporation, Chicago, USA). Simple descriptive statistics were used. An independent sample t-test was used to compare mean values. A p value of less than 0.05 was considered significant. Table 1 shows the clinical and biochemical data of the postmenopausal women with and without the metabolic syndrome. It was observed that waist circumference, body mass index, triglycerides and fasting blood sugar were significantly higher among postmenopausal women with the metabolic syndrome, but HDL cholesterol was significantly lower (p < 0.05). None of the other parameters showed any significant difference. The prevalence of the metabolic syndrome among all the study participants was 42.9%. Table 2 shows the clinical and biochemical data of postmenopausal women with and without vitamin D deficiency or insufficiency. Serum vitamin D was significantly lower among women with vitamin D deficiency or insufficiency, (p = 0.000). Triglycerides and LDL cholesterol were significantly higher among women with a deficiency or insufficiency (p < 0.05). The prevalence of vitamin D deficiency or insufficiency was 45.7%. Table 3 shows the clinical and biochemical data of the metabolic syndrome among postmenopausal women with and without vitamin D deficiency. There was no significant difference between any of the parameters except for serum vitamin D, which was significantly lower among women with vitamin D deficiency or insufficiency (p = 0.000). Among the entire study group, the prevalence of vitamin D deficiency or insufficiency was 50.7%.
Results

Discussion
This study investigates the possibility of an association between serum vitamin D levels and the metabolic syndrome and its components in a sample of postmenopausal osteoporotic women.
The prevalence of the metabolic syndrome found in the current study (42.9%) was higher than what was reported by Marjani and Moghasemi in their studies (31%) [2, 3] , and much higher than the prevalence found by Jeon et al. (13.5%) [18] . This might be explained by the fact that all the women in the current study are osteoporotic, bearing in mind that some studies suggest an association between osteoporosis and the metabolic syndrome [19, 20] . Waist circumference, body mass index, triglycerides and fasting blood sugar were significantly higher among women with the metabolic syndrome, and serum HDL was significantly lower. This is consistent with results reported by Yasein et al. and Isordia-Salas et al. [21, 22] . Since all these parameters are considered components of the metabolic syndrome, it is not surprising to find their values significantly higher among metabolic syndrome patients (except for serum HDL, which was significantly lower) [23] .
The prevalence of vitamin D deficiency or insufficiency (45.7%) was close to that reported by Holick et al. (52%) and to results from a multinational study on osteoporotic postmenopausal women including 18 countries, which reported a prevalence of 48.7% for serum vitamin D < 25 ng/ /mL-1, and a prevalence of 63.9% for serum vitamin D < 30 ng/mL-1 [24] . However, it was less than what was reported by Bruyere et al. (79.6%) [25] and higher than the results from Gorgan (Iran) by Marjani and Moghasemi (30%) [2, 24, 25] .
Women who had vitamin D deficiency or insufficiency were found to have a significantly higher level of serum triglycerides and serum LDL. Vacek et al. found a similar association between serum vitamin D and triglycerides [26] . In another study by Martins et al., the prevalence of low serum 25-hyrdoxy vitamin D was higher in patients with hypertriglyceridemia [12] . Anderson et al. found that hyperlipidemia was more prevalent among their study participants who had vitamin D deficiency at baseline [7] . Moreover, Yin et al. found that the vitamin D deficiency group in their study had significantly greater serum triglycerides, and both the deficiency and the insufficiency groups had higher serum LDL levels [27] . One suggested mechanism for the relationship between vitamin D and serum lipids (including both triglycerides and serum LDL) is that the binding of vitamin D to its receptors inhibits adipogenesis, resulting in a negative association between vitamin D levels and lipid levels [28] [29] [30] .
Women with the metabolic syndrome were investigated separately with regard to their serum vitamin D status. In this group of patients, the prevalence of vitamin D deficiency or insufficiency (50.7%) was greater than what was reported by Marjani and Moghasemi (32.26%) [2] . Again, this might be attributable to the osteoporotic nature of the current study sample, taking into consideration that low serum levels of vitamin D are common among osteoporotic women [23] .
No significant differences were found in any of the studied parameters (including the components of the metabolic syndrome) except for serum vitamin D which -obviously -was found to be significantly lower among the vitamin D deficient or insufficient group. This study's findings indicate a lack of association between serum vitamin D status and the metabolic syndrome -a result found in other studies [2, 9] . However, further research is needed in this area.
The current study has several limitations. First, the research was conducted on patients of a single family practice clinic which might limit the ability to generalize its results to the entire population of postmenopausal osteoporotic women. Second, the cross sectional design of the study cannot confirm a causation relationship. Third, serum vitamin D was measured only at a single point in time, and may not reflect the patients' long term vitamin D status.
The findings of the current study suggest a lack of relationship between serum vitamin D and the metabolic syndrome. However, a significant inverse relationship was found between serum vitamin D levels and both serum triglycerides and LDL levels. This highlights the importance of screening for vitamin D deficiencies and insufficiencies as part of the treatment of other disorders, such as dylipidemia, to decrease cardiovascular diseases and risks.
